Novo Nordisk Retained Earnings (Accumulated Deficit) 2010-2024 | NVO

Novo Nordisk retained earnings (accumulated deficit) for the quarter ending September 30, 2024 were $17.934B, a 33.9% increase year-over-year.

  • Novo Nordisk retained earnings (accumulated deficit) for 2023 were $15.223B, a 33.4% increase from 2022.
  • Novo Nordisk retained earnings (accumulated deficit) for 2022 were $11.411B, a 0.39% decline from 2021.
  • Novo Nordisk retained earnings (accumulated deficit) for 2021 were $11.456B, a 17.25% increase from 2020.

Novo Nordisk Retained Earnings (Accumulated Deficit) 2010-2024 | NVO

  • Novo Nordisk retained earnings (accumulated deficit) for 2023 were $15.223B, a 33.4% increase from 2022.
  • Novo Nordisk retained earnings (accumulated deficit) for 2022 were $11.411B, a 0.39% decline from 2021.
  • Novo Nordisk retained earnings (accumulated deficit) for 2021 were $11.456B, a 17.25% increase from 2020.
Related Stocks
Company NameMarket
Cap
Eli Lilly (LLY)$789.4B
Johnson & Johnson (JNJ)$374.3B
AbbVie (ABBV)$352.5B
Merck (MRK)$260.4B
Novartis AG (NVS)$217.6B
AstraZeneca (AZN)$200B
Pfizer (PFE)$151.4B
Sanofi (SNY)$130.2B
Innoviva (INVA)$1.3B